EUVIMEDEUVIMED entdecken
Querschnittstudie

A Cross-Sectional Study on the Prevalence and Antibiotic Resistance Trends of ESBL-Producing Escherichia Coli in UTIs in Patna Medical College & Hospital, Patna

Khushboo Kumari, Sushma Kumari, Pratulya Nandan, Vijay Kumar

International Journal of Pharmaceutical Quality Assurance · 09.07.2026 · 16 (10)

DOI: 10.25258/ijpqa.16.10.61 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 09.07.2026. Verfasst von Khushboo Kumari und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urinary tract infections (UTIs) are common worldwide, with Escherichia coli as the predominant pathogen. The emergence of extended-spectrum β-lactamase (ESBL)-producing E. coli poses a significant therapeutic challenge due to multidrug resistance.

Aim

This study aimed to determine the prevalence and antibiotic resistance patterns of ESBL-producing E. coli in patients with UTIs. Methodology: A cross-sectional study was conducted at Department of Microbiology, Patna Medical College and Hospital, Patna, India. Midstream urine samples from 326 patients with culture-confirmed UTIs were analyzed. E. coli isolates were identified using standard biochemical tests, and ESBL production was confirmed via the Combined Disk Test. Antibiotic susceptibility was assessed using the Kirby-Bauer disk diffusion method following CLSI guidelines.

Results

All 326 isolates were E. coli, with 121 (37.12%) confirmed as ESBL producers. ESBL-positive isolates showed high resistance to cefotaxime (100%), ceftriaxone (98.3%), ceftazidime (97.5%), amoxicillin (96.7%), and ciprofloxacin (84.3%). Carbapenems (meropenem, 94.2% sensitivity), nitrofurantoin (81%), and amikacin (66.1%) remained effective. ESBL prevalence was not significantly associated with age or sex but correlated strongly with cephalosporin and fluoroquinolone resistance.

Conclusion

ESBL-producing E. coli constitutes a significant proportion of UTI pathogens with extensive multidrug resistance. Carbapenems, nitrofurantoin, and aminoglycosides remain viable treatment options. Continuous surveillance and rational antibiotic use are essential to limit the spread of resistant strains.

Zitieren

APA

Kumari, K., Kumari, S., Nandan, P., & Kumar, V. (2026). A Cross-Sectional Study on the Prevalence and Antibiotic Resistance Trends of ESBL-Producing Escherichia Coli in UTIs in Patna Medical College & Hospital, Patna. International Journal of Pharmaceutical Quality Assurance, 16(10). https://doi.org/10.25258/ijpqa.16.10.61

Vancouver

Kumari K, Kumari S, Nandan P, Kumar V. A Cross-Sectional Study on the Prevalence and Antibiotic Resistance Trends of ESBL-Producing Escherichia Coli in UTIs in Patna Medical College & Hospital, Patna. International Journal of Pharmaceutical Quality Assurance. 2026;16(10). doi:10.25258/ijpqa.16.10.61

BibTeX
@article{Kumari2026,
  author = {Kumari, Khushboo and Kumari, Sushma and Nandan, Pratulya and Kumar, Vijay},
  title = {A Cross-Sectional Study on the Prevalence and Antibiotic Resistance Trends of ESBL-Producing Escherichia Coli in UTIs in Patna Medical College & Hospital, Patna},
  journal = {International Journal of Pharmaceutical Quality Assurance},
  year = {2026},
  volume = {16},
  number = {10},
  doi = {10.25258/ijpqa.16.10.61}
}
Kostenlos starten →